Rlavie Successfully Concludes CPHI Shanghai 2026

Rlavie’s CPHI Shanghai 2026 recap from booth E12D82, covering heterocyclic intermediates, custom synthesis, analytical quality and dependable supply.

From June 16–18, 2026, the Rlavie team welcomed customers, partners and industry professionals at booth E12D82 during CPHI Shanghai. The three-day event created a valuable setting for practical conversations about heterocyclic intermediates, custom synthesis, analytical expectations and dependable supply for pharmaceutical research and development.

Connecting at Booth E12D82

CPHI Shanghai brought together companies and specialists from across the pharmaceutical value chain. At the Rlavie booth, conversations moved beyond simple product availability. Visitors discussed target structures, quantity and purity requirements, route feasibility, delivery schedules and the challenges involved in moving from an initial research request to repeat supply.

These exchanges reinforced an important point: sourcing a research chemical is not only about finding a CAS number. Teams also need confidence that the requested structure has been interpreted correctly, that the proposed route is technically defensible and that the analytical package is aligned with the material’s intended use.

Capabilities We Presented

Rlavie presented its work in heterocyclic chemistry, pharmaceutical intermediates and hard-to-source building blocks. The company’s portfolio provides practical starting points for research programs, while custom synthesis supports targets that are not readily available from a standard catalogue.

For a custom target, the process begins with structure and requirement review, followed by technical evaluation, feasibility and quotation, synthesis, analytical verification and delivery. Project scope can be aligned with the development stage, from small research quantities to larger or repeat requirements, subject to technical evaluation and agreed specifications.

We also highlighted the importance of analytical clarity. Identity, chemical purity and stereochemical purity are different questions, and the appropriate evidence depends on the compound and its intended use. Aligning methods and acceptance criteria before delivery helps reduce avoidable uncertainty for both research and procurement teams.

What the Conversations Highlighted

Discussions during the exhibition repeatedly returned to three practical needs:

Feasibility before commitment. Early technical review helps distinguish a realistic route from an optimistic lead time.
Evidence aligned with intended use. Specifications and analytical methods should reflect how the material will be used, not rely on a purity number alone.
A clear path to continuity. When a project advances, teams need to understand whether the route, starting materials and quality controls can support repeat or larger-scale supply.

These are the areas where responsive technical communication matters most. A useful supplier relationship makes assumptions visible, raises risks early and keeps chemistry, quality and delivery expectations connected.

CPHI Shanghai 2026 Highlights

This short event recap was created from photographs captured during Rlavie’s participation at CPHI Shanghai 2026.

Continuing the Conversation

We sincerely thank everyone who visited booth E12D82 and shared their questions, projects and perspectives with our team. The discussions will continue to inform how Rlavie communicates technical feasibility, analytical expectations and supply options to pharmaceutical companies, CROs and research institutions worldwide.

If your team is evaluating a heterocyclic intermediate or a hard-to-source target, explore Rlavie’s custom synthesis capabilities or learn more about Rlavie. A useful project inquiry should include the target structure, required quantity, purity, intended use and preferred timing.